Table 1.
CYP2A6 substrates.
| Drugs | Assay/end-point | Toxic agents | Assay/end-point |
|---|---|---|---|
| Coumarin | 7-hydroxylation | Nicotine | N-1′-oxidation |
| Methoxyflurane | Dehalogenation | Cotinine | 3′-hydroxylation |
| Halothane | Reduction | NNK | Mutagenicity |
| SM-12502 | S-oxidation | NDEA | Mutagenicity |
| Losigamone | Oxidation | AFB1 | Mutagenicity |
| Valproic acid | Oxidation | MOCA | N-oxidation |
| Letrozole | Oxidation | 1,3-butadiene | Monoxide formation |
| Disulfiram | Sulfoxidation | Quinoline | 1-oxidation |
| DCBN | Protein adduct formation | ||
| MTBE | O-demethylation |
SM-12502, 3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride; NNK, 4-methylnitrosamino-1-(3-pyridyl)-1-butanone; NDEA, N-nitrosodiethylamine; AFB1, aflatoxin B1; MOCA, 4,4′-methylene-bis(2-chloroaniline); DCBN, 2,6-dichlorobenzonitrile; MTBE, methyl tert-butyl ether. References [6, 7, 56–59].